CVS Stock Recent News

CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CVS makes progress in stabilizing Aetna with leadership, risk management and operational changes.

Grants will support local nonprofits improving health outcomes across the Greater Hartford area HARTFORD, Conn. , Sept. 10, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) Foundation announced today that it is awarding $1 million in general operating grants through its Hometown Fund to 20 organizations surrounding the Hartford area.

Grants will support local nonprofits improving health outcomes across the state WOONSOCKET, R.I. , Sept. 10, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) Foundation announced today that it is awarding $1 million in general operating grants through its Hometown Fund to 20 Rhode Island-based organizations.

CVS Health Corporation  CVS is trading higher on Tuesday. This follows yesterday's sell-off of almost 5%.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Major U.S. equities indexes ticked higher as markets kicked off a new trading week.

CVS' diversified model, digital push and Aetna stabilization highlight a compelling investment story.

Barclays analyst Andrew Mok raised the firm's price target on UnitedHealth to $362 from $337 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

Barclays lowered the firm's price target on Molina Healthcare to $185 from $186 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 23 Oct